参考文献/References:
[1]Mao L,Huang W,Zou P,et al.The unrecognized role of tumor suppressor genes in atrial fibrillation[J]. Gene,2018,642:26-31.
[2]Cheng WL,Kao YH,Chen SA,et al. Pathophysiology of cancer therapy-provoked atrial fibrillation[J]. Int J Cardiol,2016,219:186-194.
[3]Yang X,Li X,Yuan M,et al. Anticancer therapy-induced atrial fibrillation:electrophysiology and related mechanisms[J]. Front Pharmacol,2018,9:1058.
[4]Severino P,Mariani MV,Maraone A,et al. Triggers for atrial fibrillation:the role of anxiety[J]. Cardiol Res Pract,2019,2019:1208505.
[5]Zhang S. Atrial fibrillation in mainland China:epidemiology and current management[J]. Heart,2009,95(13):1052-1055.
[6]Onaitis M,D’Amico T,Zhao Y,et al. Risk factors for atrial fibrillation after lung cancer surgery:analysis of the society of thoracic surgeons general thoracic surgery database[J]. Ann Thorac Surg,2010,90:368-374.
[7]Seesing MFJ,Borggreve AS,Ruurda JP,et al. New-onset atrial fibrillation after esophagectomy for cancer[J]. J Thorac Dis,2019,11:s831-s834.
[8]Imperatori A,Mariscalco G,Riganti G,et al. Atrial fibrillation after pulmonary lobectomy for lung cancer affects long-term survival in a prospective single-center study[J]. J Cardiothorac Surg,2012,7:4.
[9]January CT,Wann LS,Calkins H,et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation:a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society[J]. Heart Rhythm,2019,16(8):e66-e93.
[10]Zamorano JL,Lancellotti P,Mu?oz DR,et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) [J]. Eur Heart J,2016,37(36):2768-2801.
[11]Wei YC,Chen KF,Wu CL,et al. Stroke rate increases around the time of cancer diagnosis[J]. Front Neurol,2019,10:579.
[12]Hijazi Z,Lindb?ck J,Alexander JH,et al. The ABC (age, biomarkers, clinical history) stroke risk score:a biomarker-based risk score for predicting stroke in atrial fibrillation[J]. Eur Heart J,2016,37(20):1582-1590.
[13]Dardiotis E,Aloizou AM,Markoula S,et al. Cancer-associated stroke:pathophysiology,detection and management (review) [J]. Int J Oncol,2019,54(3):779-796.
[14]Steffel J,Verhamme P,Potpara TS,et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation[J].Eur Heart J,2018,39(16):1330-1393.
[15]Lee EJ,Nah HW,Kwon JY,et al. Ischemic stroke in patients with cancer:is it different from usual strokes?[J]. Int J Stroke,2014,9(4):406-412.
[16]Karlinska AG,Gromadzka G,Karlinski MA,et al. The activity of malignancy may determine stroke pattern in cancer patients[J]. J Stroke Cerebrovasc Dis,2015,24(4):778-783.
[17]Kim K,Lee JH. Risk factors and biomarkers of ischemic stroke in cancer patients[J]. J Stroke,2014,16(2):91-96.
[18]Hu WS,Lin CL. Impact of atrial fibrillation on the development of ischemic stroke among cancer patients classified by CHA2DS2-VASc score—A nationwide cohort study[J]. Oncotarget,2018,9:7623-7630.
[19]Vedovati MC,Giustozzi M,Verdecchia P,et al. Patients with cancer and atrial fibrillation treated with doacs:a prospective cohort study[J]. Int J Cardiol,2018,269:152-157.
[20]Mosarla RC,Vaduganathan M,Qamar A,et al. Anticoagulation strategies in patients with cancer:JACC review topic of the week[J]. J Am Coll Cardiol,2019,73(11):1336-1349.
[21]Russo V,Rago A,Papa AA,et al. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with malignancy:clinical practice experience in a single institution and literature review[J]. Semin Thromb Hemost,2018,44(4):370-376.
[22]Chu G,Versteeg HH,Verschoor AJ,et al. Atrial fibrillation and cancer—An unexplored field in cardiovascular oncology[J]. Blood Rev,2019,35:59-67.
[23]O’Brien EC,Simon DN,Thomas LE,et al. The ORBIT bleeding score:a simple bedside score to assess bleeding risk in atrial fibrillation[J]. Eur Heart J,2015,36(46):3258-3264.
[24]Proietti M,Hijazi Z,Andersson U,et al. Comparison of bleeding risk scores in patients with atrial fibrillation:insights from the RE-LY trial[J]. J Int Med,2018,283(3):282-292.
[25]Pourafkari L,Baghbani-Oskouei A,Savadi-Oskouei S,et al. Prediction model for significant bleeding in patients with supratherapeutic international normalized ratio after oral administration of warfarin[J]. Clin Drug Investig,2019,39:533-542.
[26]Chang TY,Lip GYH,Chen SA,et al.Importance of risk reassessment in patients with atrial fibrillation in guidelines:assessing risk as a dynamic process[J]. Can J Cardiol,2019,35(5):611-618.
[27]王彬浩,夏云龙,储慧民. 肿瘤与心房颤动的相关性分析[J].心血管病学进展,2017,38(3):277-280.
[28]Kim SA,Yhim HY,Bang SM. Current management of cancer-associated venous thromboembolism:focus on direct oral anticoagulants[J]. J Korean Med Sci,2019,34(6):e52.
[29]Malavasi VL,Fantecchi E,Gianolio L,et al. Atrial fibrillation in patients with active malignancy and use of anticoagulants:UNder-prescription but no adverse impact on all-cause mortality[J]. Eur J Intern Med,2019,59:27-33.
[30]Sato T,Aizawa Y,Fuse K,et al. The impact of cancer on major bleeding and stroke/systemic emboli in patients using direct oral anticoagulants:from the database of a single-center registry[J]. J Atr Fibrillation,2018,11(4):2105.
[31]Chen ST,Hellkamp AS,Becker RC,et al. Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer:observations from ROCKET AF[J]. Eur Heart J Qual Care Clin Outcomes,2019,5(2):145-152.
[32]Kim K,Lee YJ,Kim TH,et al. Effect of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with newly diagnosed cancer[J]. Korean Circ J,2018,48(5):406-417.
[33]Shah S,Norby FL,Datta YH,et al. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation[J]. Blood Adv,2018,2(3):200-209.
[34]Fanola CL,Ruff CT,Murphy SA,et al. Efficacy and safety of edoxaban in patients with active malignancy and atrial Fibrillation:analysis of the ENGAGE AF-TIMI 48 Trial[J]. J Am Heart Assoc,2018,7(16):e008987.
相似文献/References:
[1]白金龙 李洪仕 蔡衡.非瓣膜性心房颤动导管消融术后抗凝策略的研究进展[J].心血管病学进展,2021,(1):30.[doi:10.16806/j.cnki.issn.1004-3934.201.01.000]
[2]魏言昭 唐艳红.心房颤动患者的脑卒中风险评估及危险因素的最新进展[J].心血管病学进展,2021,(11):1032.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
WEI YanzhaoTANG Yanhong.Stroke Risk Evaluation and Risk Factors in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(5):1032.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
[3]董皓宇 杨乙珩 夏云龙.心房颤动的抗凝治疗：CHA2DS2-VASc评分之外[J].心血管病学进展,2022,(5):403.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.005]
Beyond CHADS-VASc Score.Anticoagulant Therapy for Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2022,(5):403.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.005]
[4]. 经导管主动脉瓣置换术术后抗栓治疗的研究进展 [J].心血管病学进展,2022,(7):577.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
DUAN ZhenyaWU Yongjian.Antithrombotic Therapy After Transcatheter Aortic Valve Implantation[J].Advances in Cardiovascular Diseases,2022,(5):577.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
[5]魏志梁 孙雨可 尹月娇 孙守刚.心房颤动合并慢性肾脏病患者的左心耳封堵治疗研究进展[J].心血管病学进展,2022,(9):783.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.005]
WEI Zhiliang,SUN Yuke,YIN Yuejiao,et al.Left Atrial Appendage Closure in Patients with Atrial Fibrillation Complicated with Chronic Kidney Disease[J].Advances in Cardiovascular Diseases,2022,(5):783.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.005]
[6]王昱冕 陈涵 王红.生长分化因子15与心血管疾病出血事件相关性的研究进展[J].心血管病学进展,2022,(10):928.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.015]
WANG Yumian,CHEN Han.,WANG Hong.Relationship Between Growth Differentiation Factor 15 and Cardiovascular Bleeding Events[J].Advances in Cardiovascular Diseases,2022,(5):928.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.015]
[7]加依娜·加尔肯 汤宝鹏 周贤惠 李耀东 芦颜美.非瓣膜性心房颤动患者“一站式”手术策略的有效性和安全性:单中心经验[J].心血管病学进展,2022,(12):1141.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.019]
Jiayina Jiaerken,TANG Baopeng,ZHOU Xianhui,et al.Effectiveness and Safety of "One-Step" Procedure in Patients with Non-Valvular Atrial Fibrillation:A Single Center Experience?/html>[J].Advances in Cardiovascular Diseases,2022,(5):1141.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.019]
[8]王华 陈科宇 秦永文 白元.新型卵圆孔未闭封堵器的研制及临床应用进展[J].心血管病学进展,2023,(9):781.[doi:10.16806/j.cnki.issn.1004-3934.2023.09.004]
WANG Hua,CHEN Keyu,QIN Yongwen,et al.Design and Clinical Practice of Novel Patent Foramen Ovale Occluders[J].Advances in Cardiovascular Diseases,2023,(5):781.[doi:10.16806/j.cnki.issn.1004-3934.2023.09.004]
[9]陈建福 陈灿.血压目标范围内时间与心血管疾病关系的研究进展[J].心血管病学进展,2024,(7):617.[doi:10.16806/j.cnki.issn.1004-3934.2024.07.010]
CHEN Jianfu,CHEN Can.The Relationship Between Time in Target Range and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2024,(5):617.[doi:10.16806/j.cnki.issn.1004-3934.2024.07.010]
[10]夏熠 刘飞 夏云龙.糖尿病合并心房颤动的相关研究进展[J].心血管病学进展,2020,(1):27.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.008]
XIA YiLIU FeiXIA Yunlong.Research Progress in Diabetes Mellitus Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2020,(5):27.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.008]